Summary: Cigna Healthcare modified its coverage policy for Donor Lymphocyte Infusion and Hematopoietic Progenitor Cell (HPC) Boost under policy 0261, with an effective date of 2026-05-16. Here's what billing teams need to do.
This update to the Cigna Healthcare donor lymphocyte infusion coverage policy affects hematology-oncology and bone marrow transplant billing teams who submit claims for DLI and HPC boost procedures. The policy does not list specific codes in the available data — more on that below. If your practice or facility handles stem cell transplant follow-up care, this policy change deserves your attention before May 16, 2026.
| Field | Detail |
|---|---|
| Payer | Cigna Healthcare |
| Policy | Donor Lymphocyte Infusion and Hematopoietic Progenitor Cell HPC Boost |
| Policy Code | 0261 |
| Change Type | Modified |
| Effective Date | 2026-05-16 |
| Impact Level | High |
| Specialties Affected | Hematology-Oncology, Bone Marrow Transplant Programs, Cellular Therapy |
| Key Action | Review your current DLI and HPC boost billing guidelines against the updated 0261 criteria before May 16, 2026 |
Cigna Donor Lymphocyte Infusion and HPC Boost Coverage Criteria and Medical Necessity Requirements 2026
Donor lymphocyte infusion (DLI) and hematopoietic progenitor cell boost are two distinct but related procedures. Both are used after allogeneic stem cell transplant, typically to address relapse or graft failure. That clinical context matters for medical necessity documentation — and Cigna's 0261 policy governs exactly when these services clear the bar for reimbursement.
DLI involves infusing donor-derived T-lymphocytes into a transplant recipient. The goal is to generate a graft-versus-tumor effect in patients who relapse after allogeneic transplant. HPC boost — sometimes called stem cell boost — involves infusing additional hematopoietic progenitor cells from the original donor to improve engraftment. These are not interchangeable procedures, and the medical necessity criteria for each differ.
Cigna's 0261 policy has historically required documented evidence of relapse or graft failure, confirmation of prior allogeneic transplant, and appropriate donor availability. Prior authorization is almost certainly required for both procedures under this policy — Cigna requires prior auth on most cellular therapy services, and DLI and HPC boost fall squarely in that category. Confirm your prior authorization workflow is active and mapped to the updated 0261 criteria before the May 16, 2026 effective date.
The real issue with this policy modification is that the specific changes from version to version aren't always obvious without a line-by-line diff. Medical necessity thresholds, documentation requirements, or covered indications may have shifted. Your billing team should not assume the old approval criteria still hold after May 16, 2026.
Cigna 0261 Donor Lymphocyte Infusion Exclusions and Non-Covered Indications
Cigna's coverage policy for DLI and HPC boost has historically excluded several uses. These are the areas where claim denial risk is highest.
Autologous transplant settings. DLI and HPC boost in the context of autologous (self-donor) transplant are not covered. The graft-versus-tumor mechanism requires a donor — autologous infusions don't generate that effect. Claims submitted without clear documentation of an allogeneic donor source will not survive review.
Prophylactic or preemptive DLI. Administering DLI before documented relapse — as prevention rather than treatment — has historically been considered experimental or investigational by Cigna. If your oncology team is using DLI prophylactically, that claim is a denial waiting to happen unless the policy modification specifically changed this position. Verify this with your compliance officer before billing.
Solid organ transplant follow-up. DLI and HPC boost apply to hematopoietic stem cell transplant recipients, not solid organ transplant patients. Cross-contamination of these billing scenarios is rare but not unheard of.
Unrelated or mismatched donors without documented clinical rationale. Cigna may require additional documentation when the donor is unrelated or HLA-mismatched. Missing documentation in these cases leads to medical necessity denials.
Coverage Indications at a Glance
| Indication | Status | Relevant Codes | Notes |
|---|---|---|---|
| DLI for relapsed hematologic malignancy after allogeneic transplant | Covered (when criteria met) | Not listed in policy data | Prior authorization required; document relapse clearly |
| HPC boost for graft failure after allogeneic transplant | Covered (when criteria met) | Not listed in policy data | Prior authorization required; document graft failure criteria |
| DLI for prophylactic/preemptive use (pre-relapse) | Experimental / Not Covered | Not listed in policy data | Historical Cigna position; verify against updated 0261 |
| DLI or HPC boost in autologous transplant setting | Not Covered | Not listed in policy data | No graft-versus-tumor mechanism; denials expected |
| DLI or HPC boost for solid organ transplant recipients | Not Covered | Not listed in policy data | Outside scope of this coverage policy |
| HPC boost for mismatched/unrelated donor without clinical rationale | Coverage Uncertain | Not listed in policy data | Additional documentation likely required; consult compliance officer |
Cigna Donor Lymphocyte Infusion Billing Guidelines and Action Items 2026
Here's what your billing and revenue cycle team should do right now.
| # | Action Item |
|---|---|
| 1 | Pull the full updated 0261 policy before May 16, 2026. The policy is available at Cigna's coverage policy portal. Read the updated version against whatever criteria your team has been using. If you don't have a prior version on file, get one from your payer contract team or compliance officer so you can identify what changed. |
| 2 | Audit your prior authorization workflow for DLI and HPC boost. Cigna requires prior auth for these services. Confirm your team knows which codes trigger the PA requirement and that the auth request templates reflect the updated 0261 medical necessity criteria. A prior auth approved under old criteria may not protect you from denial if the infusion happens after the effective date and the criteria have changed. |
| 3 | Update your medical necessity documentation templates. Your oncology documentation should clearly capture: the original transplant date, donor type (related vs. unrelated, allogeneic confirmed), the clinical indication (relapse with evidence, graft failure with evidence), and the treating physician's rationale. Vague documentation is the number one reason DLI and HPC boost claims get denied on medical necessity grounds. |
| 4 | Verify the specific codes your facility uses for DLI and HPC boost. The updated 0261 policy does not list specific codes in the available policy data. This is a gap you need to close internally. Work with your coding team to confirm the CPT and HCPCS codes you currently bill for these services, then cross-reference them against Cigna's current fee schedule and any coding guidance in the full policy document. Do not assume the codes in your charge capture are correct without verifying. |
| 5 | Flag any pending or scheduled DLI or HPC boost cases. If you have patients scheduled for these procedures after May 16, 2026, review those cases against the updated criteria now — not the week of the service. If the clinical picture doesn't clearly meet the updated medical necessity standard, loop in your medical director and compliance officer before the procedure happens. A denied claim for a cellular therapy service is not a small denial. |
| 6 | Check your remittance advice for denial patterns. If Cigna has already started issuing denials under a preview of the updated criteria, those will show up in your EOBs. Look for denial codes tied to medical necessity or investigational status on DLI and HPC boost claims from the last 60–90 days. |
| Previous Version | Current Version |
|---|---|
| Coverage is considered experimental and investigational for all indications | Coverage is considered medically necessary when specific criteria are met |
| Prior authorization is not required | Prior authorization is required for initial treatment |
| Documentation must include clinical history | Documentation must include clinical history |
| Re-review every 24 months | Re-review every 12 months with updated clinical documentation |
CPT, HCPCS, and ICD-10 Codes for Donor Lymphocyte Infusion and HPC Boost Under Policy 0261
The available policy data for Cigna 0261 does not include a specific list of CPT, HCPCS, or ICD-10 codes. This is not uncommon for modified policies — Cigna sometimes updates criteria documents without republishing the full code set in the same document.
This does not mean your billing team gets to skip the code verification step. It means you have to do the work directly.
What Your Coding Team Should Do
Pull the full 0261 policy document from Cigna's coverage policy portal and look for an attached code list or reference table. Cigna typically appends applicable codes to its coverage position criteria documents. If no code list is attached, contact your Cigna provider relations representative and ask specifically for the procedure codes covered under policy 0261.
Common procedure categories that apply to DLI and HPC boost billing — based on standard CPT and HCPCS coding conventions — include cellular therapy infusion codes, apheresis product codes, and stem cell processing codes. But do not bill from memory or assumption. Confirm the exact codes with Cigna and your coding team before the effective date of May 16, 2026.
If you're not sure how this applies to your specific facility's charge capture or code mix, talk to your compliance officer or billing consultant before May 16, 2026.
Get the Full Picture
Track this policy across versions, search 1,500+ policies by CPT code, and get real-time alerts when any payer changes coverage.